Evidence map›Paper›PMID 24760005›Full record

ArticlePloS one2014

Specific activation of K-RasG12D allele in the bladder urothelium results in lung alveolar and vascular defects.

Francisco Ayala de la Peña, Keizo Kanasaki, Megumi Kanasaki, Sylvia Vong, Carlota Rovira, Raghu Kalluri

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Francisco Ayala de la PeñaDivision of Matrix Biology/Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America.
Keizo KanasakiDivision of Matrix Biology/Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America.
Megumi KanasakiDivision of Matrix Biology/Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America.
Sylvia VongDivision of Matrix Biology/Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America.
Carlota RoviraDepartment of Pathology, Hospital Sant Joan de Deu, Esplugues de Llobregat, Barcelona, Spain.
Raghu KalluriDepartment of Cancer Biology, Metastasis Research Center, University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America.
Beth Israel Deaconess Medical Center · USHarvard University · USHospital Sant Joan de Déu Barcelona · ESThe University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
TYPE IV COLLAGEN IN ALPORT SYNDROME PATHOGENESISR01DK055001 · NIDDK · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU · 1999 to 2014
$4.3M
Regulation of Angiogenesis by TumstatinR01DK062987 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KALLURI, RAGHU · 2003 to 2006
$1.4M
Role of Fibroblasts in CancerR01CA125550 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KALLURI, RAGHU · 2008 to 2010
$1.1M
Matrix Microenvironment and Liver FibrosisR01AA013913 · NIAAA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KALLURI, RAGHU · 2005 to 2007
$994k
The Biology and Function of BMP-7 in the KidneyR01DK061688 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KALLURI, RAGHU · 2005 to 2007
$746k
NCI NIH HHS CA125550NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA125550NIAAA NIH HHS AA13913NIAAA NIH HHS R01 AA013913NIDDK NIH HHS DK55001NIDDK NIH HHS DK61688NIDDK NIH HHS DK62987NIDDK NIH HHS R01 DK055001NIDDK NIH HHS R01 DK061688NIDDK NIH HHS R01 DK062987
6 · The paper itself

Abstract

K-ras is essential for embryogenesis and its mutations are involved in human developmental syndromes and cancer. To determine the consequences of K-ras activation in urothelium, we used uroplakin-II (UPK II) promoter driven Cre recombinase mice and generated mice with mutated KrasG12D allele in the urothelium (UPK II-Cre;LSL-K-rasG12D). The UPK II-Cre;LSL-K-rasG12D mice died neonatally due to lung morphogenesis defects consisting of simplification with enlargement of terminal air spaces and dysmorphic pulmonary vasculature. A significant alteration in epithelial and vascular basement membranes, together with fragmentation of laminin, points to extracellular matrix degradation as the causative mechanism of alveolar and vascular defects. Our data also suggest that altered protease activity in amniotic fluid might be associated with matrix defects in lung of UPK II-Cre;LSL-K-rasG12. These defects resemble those observed in early stage human neonatal bronchopulmonary dysplasia (BPD), although the relevance of this new mouse model for BPD study needs further investigation.

Indexed as

AllelesAnimalsFemaleGenes, rasIntegrasesLungMaleMiceMice, TransgenicUrinary BladderUroplakin IIUrotheliumCre recombinaseIntegrasesUroplakin II

Identifiers

PMID24760005
PMCPMC3997426
OpenAlexW2129450192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.